Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Centrally acting muscle relaxant. Oral administration in a daily dose.
At the time of the last update, we found no published data on its excretion in breast milk.
Its pharmacokinetic data: low molecular weight, high fat solubility (Acorda 2006), make it likely to pass into milk in quantities that could be significant.
Expert authors state that if the mother needs to take tizanidine, this is not a reason to interrupt breastfeeding (Hale). Other authors consider it prudent to avoid it during breastfeeding (Hutchinson 2013) or to use it very sporadically and limit it to the minimum sufficient dose. In any case, it is advisable to monitor the infant for possible sedation and/or poor weight gain, especially in the first 3 months of life and when breastfeeding is exclusive.